202577-32-0Relevant articles and documents
Process development of a potent glucosylceramide synthase inhibitor
Cooper, Christopher G.F.,Lee, Edward R.,Silva, Richard A.,Bourque, Andre J.,Clark, Scott,Katti, Sanjeev,Nivorozhkin, Vitaly
scheme or table, p. 1090 - 1097 (2012/08/27)
An economic, scalable process for the production of glucosylceramide synthase (GCS) inhibitor 7 has been developed. Herein we report a three-step synthesis to aldehyde 4 with high yield and purity that employs the selective cleavage of an endocyclic C-O b
Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man
Wennekes, Tom,Van Den Berg, Richard J. B. H. N.,Donker, Wilma,Van Der Marel, Gijsbert A.,Strijland, Anneke,Aerts, Johannes M. F. G.,Overkleeft, Herman S.
, p. 1088 - 1097 (2007/10/03)
(Chemical Equation Presented) In this article, we present a straightforward synthesis of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives. The used synthetic routes are flexible and can be used to create a wide variety of lipophilic mo
Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
-
, (2008/06/13)
Deoxynojirimycin derivatives containing a large hydrophobic moiety, such as cholesterol or adamantame-methanol, linked through a spacer, such as pentamethylene, to the nitrogen atom of deoxynojirimycin, and salts thereof, inhibit glucosylceramidase and may be useful in the treatment of diseases involving a ceramide-mediated signaling process, such as Gaucher disease.
